The TRISTAN ILD Study
Research type
Research Study
Full title
Development of imaging biomarkers for the detection and monitoring of drug induced interstitial lung disease
IRAS ID
232495
Contact name
Ian Bruce
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
6 years, 1 months, 1 days
Research summary
Interstitial lung disease (ILD) is a condition where inflammation and scarring occurs in the lung causing patients to become breathless. There are a number of underlying causes of ILD including rheumatic conditions such as rheumatoid arthritis and reactions to drugs (known as drug induced ILD or DIILD). Over 350 drugs are known to cause DIILD. As reactions can occur rarely and often a long time after drug administration it can be sometimes be hard to identify drugs with the potential to harm the lungs in clinical trials. The current methods to detect and track ILD, including breathing tests (spirometry) are not very sensitive in early disease or for detecting underlying cause.
Advances in imaging tests including MRI and CT may allow more detailed assessment of the lungs and could potentially be used to detect early lung injury or track changes in lung inflammation. The aim of the current study is to evaluate whether measurements on lung MRI and CT scans are associated with current standard measurements of lung function in patients with ILD and provide further information about ILD. We also want to assess if there are differences in the scans in patients with ILD due to drugs rather than other causes of ILD e.g. rheumatoid arthritis.
In order to do this we propose to conduct an observational study of ILD patients using standard assessments used in clinical practice such as spirometry and also MRI and CT scans. We would like to follow patients up over a period of time and see if changes on scans reflect change in lung function. Results from this study will allow us to identify if any of the MRI and CT methods could be taken forward into a larger study to validate them for use in clinical trials and clinical practice.REC name
North West - Preston Research Ethics Committee
REC reference
17/NW/0631
Date of REC Opinion
13 Nov 2017
REC opinion
Further Information Favourable Opinion